Carl Zeiss Meditec Group achieves first half 2016/17 revenue of approximately €588m
Publication of insider information pursuant to Art. 17 MAR1
Jena/Germany | Carl Zeiss Meditec AG
Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately €588m (prior year: €540.8m) in the first half of fiscal year 2016/17, based on preliminary data. This corresponds to a revenue growth rate vs. the previous year of 8.7%. From today’s point of view, the Group expects operating earnings (EBIT) significantly above previous year’s level of €75.3m.
The half year financial report 2016/17 will be published on 10 May 2017.
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med